Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • Patent number: 8901155
    Abstract: A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]: wherein A represents a lower alkylene group or a lower alkenylene group; R1 represents a hydrogen atom, an unsubstituted or substituted alkyl group or an unsubstituted or substituted alkenyl group; and R2 and R3 are the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: December 2, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji Oki, Fumio Tsuji, Chikako Setoguchi, Iwao Seki, Masaaki Murai, Minoru Sasano
  • Patent number: 8865654
    Abstract: An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmacologically acceptable salt thereof. The concentration ratio between SSSR or a pharmacologically acceptable salt thereof and FGLM or a pharmacologically acceptable salt thereof is between 1/15 and 1/50. The concentration of SSSR or a pharmacologically acceptable salt thereof is between 0.001% and 0.3% (w/v) and the concentration of FGLM or a pharmacologically acceptable salt thereof is between 0.015% and 1.5% (w/V). The pH of the eye drop is maintained between 2.5 and 6.5.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: October 21, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Takahiro Nakamura, Yuichiro Nakada, Takashi Nagano, Masatsugu Nakamura
  • Publication number: 20140243320
    Abstract: A compound represented by the following general formula (1) or a salt thereof. R1 represents a halogen atom and so on; R2 and R3 each represent a hydrogen atom and so on; R4 and R5 each represent a hydrogen atom and so on, or R4 and R5 may form an oxo group; Ra and Rb each represent a lower alkyl group optionally having a substituent and so on, or they may bind to each other to form a nitrogen-containing heterocyclic ring which may be substituted by one or plural Rc; Rc represents an aryl group optionally having a substituent and so on; ring A represents a benzene ring and so on; and m represents 0, 1 or 2.
    Type: Application
    Filed: July 12, 2012
    Publication date: August 28, 2014
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Honda, Hiroshi Enomoto, Kenji Kawashima, Shinji Takaoka, Yasutaka Fujioka, Mamoru Matsuda, Koji Ohashi, Yukie Fujita, Shin-ichiro Hirai, Hiroaki Kurashima
  • Patent number: 8802869
    Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: August 12, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
  • Publication number: 20140221306
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent, formation of insoluble precipitates found in Diquafosol ophthalmic solution during its storage, as well as deterioration of the filtration performance in the course of production (filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, enhancement of preservative effectiveness has been confirmed. Accordingly, the present invention provides Diquafosol ophthalmic solution having physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient. Particularly in the course of production, the solution can be subjected to efficient filtration sterilization. Moreover, the solution has excellent preservative effectiveness.
    Type: Application
    Filed: December 27, 2011
    Publication date: August 7, 2014
    Applicant: Santen Pharmaceutical Co. Ltd
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20140194461
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • Patent number: 8758435
    Abstract: An intraocular lens comprises an optic and at least two haptics. Each haptic is offset in an anterior direction from a central optic plane of the optic. The offset allows for predictable posterior vaulting upon implantation.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: June 24, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Anand Doraiswamy, Jensen Buck, Daniel Hamilton
  • Publication number: 20140124542
    Abstract: A fixed amount discharge container includes: a syringe barrel 3; and a piston 8 inserted in the syringe barrel 3 so as to be movable in a longitudinal direction, thereby defining a fluid chamber between the syringe barrel 3 and the piston 8. One of the syringe barrel 3 and the piston 8 includes a guide 3c that is extended in a longitudinal direction. The other of the syringe barrel 3 and the piston 8 includes a slider 9 that is movable in the guide 3c along with the other of the syringe barrel 3 and the piston 8. The guide 3c is provided with a target position contact portion 3j which the slider 9 contacts when an amount of the fluid chamber is equal to a target amount.
    Type: Application
    Filed: April 26, 2012
    Publication date: May 8, 2014
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Kojima, Nobuo Yokouchi, Naoki Kato, Kenji Kaitsuka, Takeshi Iida
  • Patent number: 8686006
    Abstract: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR4)—, —(CR5R6)— or the like; B represents an alkylene group or an alkenylene group; R1 represents an alkyl group, an alkenyl group or the like; R2 represents an adamantylalkyl group or the like; R3 represents an unsaturated heterocyclic ring; R4, R5 and R6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: April 1, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masayuki Umeda, Akio Kimura, Kenji Ueda, Koji Sakanaka
  • Publication number: 20140088039
    Abstract: An aqueous ophthalmic solution containing hyaluronic acid or a salt thereof at a concentration from 0.03 to 0.5% (w/v) and propylene glycol at a concentration from 0.1 to 1.0% (w/v) comprises as a sole preservative, benzalkonium chloride at a concentration from 0.001 to 0.002% (w/v) and comprises an ionic tonicity agent at such a concentration that an osmotic pressure ratio of the ophthalmic solution becomes from 0.9 to 1.1.
    Type: Application
    Filed: June 22, 2012
    Publication date: March 27, 2014
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji Inagaki, Toshihiro Ogawa, Yoshihide Horibe, Atsuyoshi Dota, Takashi Nagano, Masatsugu Nakamura, Yuichiro Nakada
  • Patent number: 8663639
    Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: March 4, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Philippe J. M. Dor, Sreenivasu Mudumba, Thierry Nivaggioli, David A. Weber, Sidiq Farooq, Sudeep Takhar
  • Patent number: 8664221
    Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: March 4, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Kenji Oki, Mamoru Matsuda, Toshiyuki Mori
  • Patent number: D704331
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 6, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Manthan Patel, Carolyn Finney, Jensen Buck, Anand Doraiswamy
  • Patent number: D704830
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 13, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Jensen Buck, Manthan Patel, Carolyn Finney, Anand Doraiswamy
  • Patent number: D704831
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 13, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Jensen Buck, Manthan Patel, Carolyn Finney, Anand Doraiswamy
  • Patent number: D704832
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 13, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Manthan Patel, Carolyn Finney, Jensen Buck, Anand Doraiswamy
  • Patent number: D704833
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 13, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Carolyn Finney, Manthan Patel, Jensen Buck, Anand Doraiswamy
  • Patent number: D707821
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 24, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Anand Doraiswamy, Jensen Buck, Manthan Patel, Carolyn Finney
  • Patent number: D712265
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 2, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Yoshitaka Tahara, Yoshiyuki Azuma, Tsuyoshi Kakiuchi, Hiroshi Yamada
  • Patent number: D718129
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: November 25, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Yamada, Tsuyoshi Kakiuchi